Literature DB >> 18174241

TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.

Elizabeth C Finger1, Ryan S Turley, Mei Dong, Tam How, Timothy A Fields, Gerard C Blobe.   

Abstract

The transforming growth factor-beta (TGF-beta) superfamily has essential roles in lung development, regulating cell proliferation, branching morphogenesis, differentiation and apoptosis. Although most lung cancers become resistant to the tumor suppressor effects of TGF-beta, and loss or mutation of one of the components of the TGF-beta signaling pathway, including TbetaRII, Smad2 and Smad4 have been reported, mutations are not common in non-small cell lung cancer (NSCLC). Here we demonstrate that the TGF-beta superfamily co-receptor, the type III TGF-beta receptor (TbetaRIII or betaglycan) is lost in the majority of NSCLC specimens at the mRNA and protein levels, with loss correlating with increased tumor grade and disease progression. Loss of heterozygosity at the TGFBR3 genomic locus occurs in 38.5% of NSCLC specimens and correlates with decreased TbetaRIII expression, suggesting loss of heterozygosity as one mechanism for TbetaRIII loss. In the H460 cell model of NSCLC, restoring TbetaRIII expression decreased colony formation in soft agar. In the A549 cell model of NSCLC, restoring TbetaRIII expression significantly decreased cellular migration and invasion through Matrigel, in the presence and absence of TGF-beta1, and decreased tumorigenicity in vivo. In a reciprocal manner, shRNA-mediated silencing of endogenous TbetaRIII expression enhanced invasion through Matrigel. Mechanistically, TbetaRIII functions, at least in part, through undergoing ectodomain shedding, generating soluble TbetaRIII, which is able to inhibit cellular invasiveness. Taken together, these results support TbetaRIII as a novel tumor suppressor gene that is commonly lost in NSCLC resulting in a functional increase in cellular migration, invasion and anchorage-independent growth of lung cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18174241     DOI: 10.1093/carcin/bgm289

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  51 in total

Review 1.  Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.

Authors:  Karthikeyan Mythreye; Gerard C Blobe
Journal:  Cell Signal       Date:  2009-05-08       Impact factor: 4.315

2.  Sequencing of TGF-beta pathway genes in familial cases of intracranial aneurysm.

Authors:  Teresa Santiago-Sim; Sumy Mathew-Joseph; Hariyadarshi Pannu; Dianna M Milewicz; Christine E Seidman; J G Seidman; Dong H Kim
Journal:  Stroke       Date:  2009-03-19       Impact factor: 7.914

3.  Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

Authors:  S J Cooper; H Zou; S N Legrand; L A Marlow; C A von Roemeling; D C Radisky; K J Wu; N Hempel; V Margulis; H W Tun; G C Blobe; C G Wood; J A Copland
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

4.  A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma.

Authors:  Melissa Rotunno; Nan Hu; Hua Su; Chaoyu Wang; Alisa M Goldstein; Andrew W Bergen; Dario Consonni; Angela C Pesatori; Pier Alberto Bertazzi; Sholom Wacholder; Joanna Shih; Neil E Caporaso; Phil R Taylor; Maria Teresa Landi
Journal:  Cancer Prev Res (Phila)       Date:  2011-07-08

5.  Downregulation of microRNA-193-3p inhibits the progression of intrahepatic cholangiocarcinoma cells by upregulating TGFBR3.

Authors:  Yu-Long Han; Jia-Jun Yin; Jian-Jun Cong
Journal:  Exp Ther Med       Date:  2018-03-14       Impact factor: 2.447

6.  Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells.

Authors:  Maree Bilandzic; Simon Chu; Yao Wang; Han L Tan; Peter J Fuller; Jock K Findlay; Kaye L Stenvers
Journal:  Mol Endocrinol       Date:  2013-01-15

7.  The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.

Authors:  Jason D Lee; Nadine Hempel; Nam Y Lee; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

8.  Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.

Authors:  Erik H Knelson; Angela L Gaviglio; Jasmine C Nee; Mark D Starr; Andrew B Nixon; Stephen G Marcus; Gerard C Blobe
Journal:  J Clin Invest       Date:  2014-06-17       Impact factor: 14.808

9.  Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2.

Authors:  Kelly J Gordon; Kellye C Kirkbride; Tam How; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2008-12-04       Impact factor: 4.944

10.  Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.

Authors:  Nadine Hempel; Tam How; Simon J Cooper; Tyler R Green; Mei Dong; John A Copland; Christopher G Wood; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2008-02-24       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.